Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expired OTCs, formula cost Walmart $775,000 in N.J.

This article was originally published in The Tan Sheet

Executive Summary

Walmart agrees to pay $775,000 and revise its practices to comply with New Jersey laws after a judge finds the firm sold expired infant formula and nonprescription drugs. The state court ruling found the N.J. Office of the Attorney General proved four of the eight counts in a 2008 lawsuit, including that Walmart sold items at incorrect prices, the AG said Oct. 19. The remaining counts, for questionable business practices and other violations, are to be decided in a trial in Hudson County. Under the settlement, the firm will pay $500,000 in penalties, reimburse the state $160,000 for legal expenses and $40,000 for investigative costs, and pay $75,000 for a consumer education initiative. The settlement requires Walmart to periodically inspect OTC drugs and infant formula and monitor merchandise price accuracy at New Jersey stores. Walmart admitted no wrongdoing in the settlement that supersedes a 2004 consent order the firm and state made to resolve similar issues

You may also be interested in...



Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.

Unprecedented To Lawful: Regulatory Precedent Needed For Cannabinoids’ Use In Supplements?

“This is truly uncharted territory because we’ve never had this situation,” says CHPA regulatory VP David Spangle. Asking Congress instead to instruct FDA to first determine a safe daily limit would be a threatening precedent for the supplement market, says CRN CEO Steve Mister. “That really turns DSHEA on its head.”

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel